Marco Advisor generates diagnostic, prognostic and therapeutic recommendations for Ovarian Cancer directly from clinical records in the hospital information system. The system integrates biomarkers such as BRCA1/2 and HRD with ESMO/NCCN guidelines to deliver structured, auditable recommendations to the treating team.
Some answers to questions we often receive
Marco Advisor connects to existing HIS/EMR systems via standard APIs (HL7 FHIR), requiring no data migration. It reads structured fields from Ovarian Cancer patient records and returns recommendations directly in the usual clinical interface, minimizing workflow disruption.
Yes. Marco Advisor's evidence engine updates continuously with ESMO/NCCN guidelines and relevant clinical trials for Ovarian Cancer. Recommendation changes are reflected automatically without manual updates by the clinical team.
Yes. Marco Advisor automatically cross-references clinical records with current Ovarian Cancer guidelines and identifies opportunities such as indicated but unrequested molecular testing (BRCA1/2 and HRD), therapy line changes per progression criteria, or available clinical trial eligibility, generating alerts to the treating team.
Marco Advisor generates three recommendation categories: diagnostic (alerts on pending testing such as BRCA1/2 and HRD), prognostic (risk stratification by stage and molecular factors) and therapeutic (treatment recommendations aligned with ESMO/NCCN guidelines, interaction alerts and contraindications).
Marco Advisor processes data within the hospital environment (on-premise or private cloud), without transmitting identifiable information to external servers. The system complies with health data protection regulations (HIPAA, GDPR and local norms) with full audit trails of access and data use.
Marco Advisor implementation is modular: it can start with the oncology service or Ovarian Cancer tumor board and scale gradually. The Marco team supports implementation with HIS connector configuration, local clinical validation and team training, with continuous post-implementation support.
BRCA/HRD testing in advanced ovarian cancer is not always requested before first line, missing the opportunity to optimize treatment with PARP inhibitors.